Eli Lilly's stock suffered a nearly 12% loss in markets Thursday despite strong earnings, in what analysts say is an ...

Investors are worried Novo Nordisk's competition with Eli Lilly is heating up and that the first-to-market GLP-1 leader is ...

Looking at surging obesity drug sales, market share momentum, and an increased fair value estimate, here’s what we think of ...

Eli Lilly is proving that being second but better can also pay. Zepbound, the American firm’s weight-loss jab, was approved ...

A new federal ruling means that patients will no longer have access to cheaper versions of Eli Lilly weight loss and diabetes ...

We expect disappointing results in the first quarter will be balanced by higher-than-anticipated growth in the second half.

Dive deeper with STAT+. Gain unlimited access to expert analysis, newsletters, events, and news alerts.

WeightWatchers isn’t the only company to feel the disruptive power of the weight loss drugs. London-listed but Irish-based ...

Founded in 1963 by Jean Nidetch, WeightWatchers began as a weekly weight-loss support group with just 400 attendees. It quickly grew into a global phenomenon, attracting millions of members worldwide ...

Country is poised to offer growth-channel opportunities for global pharma companies ready to scale access, innovation, and ...

A U.S. federal judge has sided with a U.S. regulator's decision last year to take Eli Lilly’s blockbuster weight loss and ...

Hims & Hers stock has surged due to impressive quarterly results, rapid weight-loss product expansion, and a strategic Novo ...